Vir Biotechnology Stock Performance
| VIR Stock | USD 7.12 0.17 2.45% |
The entity has a beta of 2.54, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vir Biotechnology will likely underperform. At this point, Vir Biotechnology has a negative expected return of -0.16%. Please make sure to validate Vir Biotechnology's value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Vir Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vir Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest unsteady performance, the Stock's forward indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 2.45 | Five Day Return (11.11) | Year To Date Return (32.26) | Ten Year Return (49.22) | All Time Return (49.22) |
1 | Disposition of 18000 shares by Sato Vicki L of Vir Biotechnology at 24.662 subject to Rule 16b-3 | 09/17/2024 |
2 | Disposition of 10028 shares by George Scangos of Vir Biotechnology at 10.0456 subject to Rule 16b-3 | 09/20/2024 |
3 | Insider Trading | 10/01/2024 |
4 | Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference | 10/03/2024 |
5 | Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 | 10/15/2024 |
6 | Acquisition by George Scangos of 598270 shares of Vir Biotechnology subject to Rule 16b-3 | 10/23/2024 |
7 | Vir Biotechnology, Inc. Reports Q3 Loss, Lags Revenue Estimates | 10/31/2024 |
8 | Earnings Update Vir Biotechnology, Inc. Just Reported And Analysts Are Trimming Their Forecasts | 11/04/2024 |
9 | Disposition of 2347 shares by De Verneuil Vanina of Vir Biotechnology at 9.4696 subject to Rule 16b-3 | 11/05/2024 |
10 | Disposition of 4397 shares by De Verneuil Vanina of Vir Biotechnology at 10.11 subject to Rule 16b-3 | 11/06/2024 |
11 | Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The... | 11/15/2024 |
12 | Vir Biotechnology Hits New 12-Month Low Should You Sell | 11/20/2024 |
| Begin Period Cash Flow | 868 M |
Vir |
Vir Biotechnology Relative Risk vs. Return Landscape
If you would invest 835.00 in Vir Biotechnology on August 27, 2024 and sell it today you would lose (123.00) from holding Vir Biotechnology or give up 14.73% of portfolio value over 90 days. Vir Biotechnology is generating negative expected returns assuming volatility of 4.2726% on return distribution over 90 days investment horizon. In other words, 38% of stocks are less volatile than Vir, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Vir Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vir Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vir Biotechnology, and traders can use it to determine the average amount a Vir Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0382
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VIR |
Estimated Market Risk
| 4.27 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vir Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vir Biotechnology by adding Vir Biotechnology to a well-diversified portfolio.
Vir Biotechnology Fundamentals Growth
Vir Stock prices reflect investors' perceptions of the future prospects and financial health of Vir Biotechnology, and Vir Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vir Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (91.85) % | ||||
| Current Valuation | 178.91 M | ||||
| Shares Outstanding | 137.72 M | ||||
| Price To Earning | 3.16 X | ||||
| Price To Book | 0.79 X | ||||
| Price To Sales | 12.47 X | ||||
| Revenue | 86.18 M | ||||
| Gross Profit | 1.03 B | ||||
| EBITDA | (684.3 M) | ||||
| Net Income | (615.06 M) | ||||
| Cash And Equivalents | 2.2 B | ||||
| Cash Per Share | 16.55 X | ||||
| Total Debt | 124.54 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.79 X | ||||
| Book Value Per Share | 9.08 X | ||||
| Cash Flow From Operations | (778.78 M) | ||||
| Earnings Per Share | (3.93) X | ||||
| Market Capitalization | 980.57 M | ||||
| Total Asset | 1.92 B | ||||
| Retained Earnings | (237.82 M) | ||||
| Working Capital | 1.41 B | ||||
About Vir Biotechnology Performance
Assessing Vir Biotechnology's fundamental ratios provides investors with valuable insights into Vir Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vir Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 42.86 | 38.10 | |
| Return On Tangible Assets | (0.33) | (0.34) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.32) | (0.30) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Vir Biotechnology performance evaluation
Checking the ongoing alerts about Vir Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vir Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vir Biotechnology generated a negative expected return over the last 90 days | |
| Vir Biotechnology has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 86.18 M. Reported Net Loss for the year was (615.06 M) with profit before taxes, overhead, and interest of 1.03 B. | |
| Vir Biotechnology has about 2.2 B in cash with (778.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vir Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Vir Biotechnology Hits New 12-Month Low Should You Sell |
- Analyzing Vir Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vir Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Vir Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vir Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vir Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vir Biotechnology's stock. These opinions can provide insight into Vir Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.